Abstract
Purpose: tо estimate the effectiveness of complete corneal ring (MyoRing) implantation compared with MyoRing implantation combined with corneal collagen crosslinking (CXL) for keratoconus treatment for 36 months follow-up. Patients and Methods. There were 101 patients (124 eyes) with progressing keratoconus aged 18–59 years in the study. Intracorneal rings were implanted in all patients. The patients were divided into 2 groups. MyoRing implantation was performed in a series of 59 patients (76 eyes) with keratoconus II–III Amsler classification, 42 patients (48 eyes) had MyoRing implantation combined with CXL. Implantation of a MyoRing in the corneal pocket was performed using a PocketMaker microkeratome and corneal intrastromal implantation system. Results. Keratometry was reduced in both groups; after MyoRing implantation for 8,45 D and MyoRing combined with CXL for 7,44 D, the spherical equivalent decreased for 7,72 and 6,29 D respectively, after 36 months. The cylinder decreased to 3,33 D with MyoRing alone and to 3,11 D with MyoRing combined with CXL. The smallest corneal thickness remained stable during 36 months after the procedure. There was an improvement in uncorrected and corrected visual acuity, and the difference in the CRF within the period of up to 12 months after the operation. It can be explained by the pseudochase formation in the group with a combined procedure. Conclusion. The implantation of the MyoRing IRC and the combination of MyoRing with CXL showed efficacy and safety in stabilizing keratoconus stabilization, as well as correction of comorbided ametropia 3 years after surgery. Both MyoRing implantation and MyoRing combined with CXL were effective in the stabilization of progressive keratoconus, as well as the correction of ametropia 3 years after surgery. There was no significant difference in MyoRing implantation and its combination with corneal crosslinking in visual and refractive results. The refractive power of the cornea was only one exeption. Long follow-up and randomized prospective studies with a large number of patients are needed.
Highlights
При кератоконусе роговица приобретает конусообраз‐ ную форму, что способствует появлению неправильного астигматизма, увеличению аберраций высшего порядка и впоследствии оказывает неблагоприятное влияние на качество зрения пациента
There was no significant difference in MyoRing implantation and its combination with corneal crosslinking in visual and refractive results
Collagen cross-linking in early keratoconus with riboflavin in a femtosecond laser-created pocket: initial clinical results
Summary
ГБУ «Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан» ул. Цель: провести сравнительную оценку эффективности лечения кератоконуса путем имплантации роговичного кольца MyoRing и сочетания имплантации кольца с кросслинкингом роговицы в отдаленные сроки. Пациенты были разделены на 2 группы: контрольную составили 59 пациентов (76 глаз), которым имплантировали ИРК, основную — 42 пациента (48 глаз), у которых имплантация MyoRing сочеталась с кросслинкингом роговицы (CXL). Через 36 месяцев после проведенного лечения в обеих группах наблюдалось снижение средних значений преломляющей силы роговицы: в контрольной — на 8,45 D и в основной — на 7,44 D, роговичный астигматизм снизился на 3,33 и на 3,11 D, сферический эквивалент — на 7,72 и 6,29 D соответственно. Имплантация ИРК MyoRing и сочетание MyoRing с CXL показали эффективность и безопасность в отношении стабилизации прогрессирующего кератоконуса, а также коррекции сопутствующих аметропий через 3 года после операции. Сравнительные результаты имплантации роговичного кольца MyoRing и сочетанного применения имплантации MyoRing с кросслинкингом роговицы у пациентов с кератоконусом.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
